Form 4 for YARW Yarrow Bioscience, Inc.
Accepted 2022-06-02 00:00:00 ET · period of report 2022-05-31 · accession 0001209191-22-033544 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-02 | 2022-05-31 | YARW | Zeronda Tyler | CFO | A - Grant | $0.35 | +12.5K | 174.1K | +8% | +$4,378 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-31 | A | A | 12,510 | $0.35 | 174,066 | D | — | — | (F1) These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2021 and ending on May 31, 2022 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2022 (the last trading day of the offering period). |